Market Research Logo

Gastrointestinal Diseases Drug Development Pipeline Review, 2018

Gastrointestinal Diseases Drug Development Pipeline Review, 2018

Summary

Gastroenteritis is an infection of the gut. Symptoms include stomach pain, cramping, fever, nausea, and a headache. Causes of gastroenteritis include contaminated food or water and contact with someone who has the virus. Treatment includes antibiotics, anti-emetic and anti-diarrheal medications. There are 12 products in development for this indication.

Enterocolitis is an inflammation of the large and small intestines. Symptoms include fever, abdominal swelling, nausea, diarrhea, rectal bleeding and sluggishness. Causes of enterocolitis include inflammation of the intestinal tissues, delayed gastric emptying, abdominal wall erythema, apnea, sepsis and cardiovascular collapse. Treatment includes antibiotics. There are eight products in development for this indication.

Gastritis is characterized by inflammation or swelling of the lining of the stomach. Acute gastritis lasts for a short period of time while chronic gastritis lasts for a long period of time (months to years). Gastritis can be caused by medications such as ibuprofen, aspirin, naproxen on long periods of consumption, excess intake of alcohol, Helicobacter pylori infection, certain autoimmune disorders, bile reflux, substance abuse (cocaine), consumption of corrosive or caustic substances such as poisons, extreme stress, viral infections and trauma.

The symptoms of gastritis may include loss of appetite, nausea and vomiting, abdominal pain and black stools. Treatment includes use of antacids, histamine 2 (H2) antagonists and proton pump inhibitors. There are 11 products in development for this indication.

Peritonitis is inflammation of the peritoneum. There are two types of peritonitis. Spontaneous bacterial peritonitis is the result of an infection of the fluid in the peritoneal cavity. Secondary peritonitis is usually due to an infection that has spread from the digestive tract. Symptoms include abdominal bloating, nausea and vomiting, diarrhea, fatigue, fever and chills. Treatment includes antibiotics. There are seven products in development for this indication.

Molecular targets in development for gastrointestinal diseases include toll-like receptors, interleukin receptors and bacterial proteins. Companies operating in this pipeline space include Kyowa Hakko Kirin, RedHill Biopharma and GlaxoSmithKline.

This report “Gastrointestinal Diseases Drug Development Pipeline Review, 2018” provides an overview of the pipeline landscape for gastrointestinal diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for gastroenteritis, enterocolitis, gastritis and peritonitis, and features dormant and discontinued products.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Gastrointestinal Diseases Report Coverage
    • Gastroenteritis – Overview
    • Enterocolitis – Overview
    • Gastritis – Overview
    • Peritonitis – Overview
  • Therapeutics Development
    • Gastroenteritis
      • Pipeline Overview
        • Table Figure 1: Number of Products under Development for Gastroenteritis
        • Table Number of Products under Development for Gastroenteritis
      • Pipeline by Companies
        • Table Figure 2: Number of Products under Development by Companies, Gastroenteritis
        • Table Number of Products under Development by Companies, Gastroenteritis
      • Pipeline by Universities/Institutes
        • Table Figure 3: Number of Products under Development by Universities/Institutes, Gastroenteritis
        • Table Number of Products under Development by Universities/Institutes, Gastroenteritis
      • Products under Development by Companies
        • Table Products under Development by Companies, Gastroenteritis
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Gastroenteritis
    • Enterocolitis
      • Pipeline Overview
        • Table Figure 4: Number of Products under Development for Enterocolitis
        • Table Number of Products under Development for Enterocolitis
      • Pipeline by Companies
        • Table Figure 5: Number of Products under Development by Companies, Enterocolitis
        • Table Number of Products under Development by Companies, Enterocolitis
      • Pipeline by Universities/Institutes
        • Table Number of Products under Development by Universities/Institutes, Enterocolitis
      • Products under Development by Companies
        • Table Products under Development by Companies, Enterocolitis
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Enterocolitis
    • Gastritis
      • Pipeline Overview
        • Table Figure 6: Number of Products under Development for Gastritis
        • Table Number of Products under Development for Gastritis
      • Pipeline by Companies
        • Table Figure 7: Number of Products under Development by Companies, Gastritis
        • Table Number of Products under Development by Companies, Gastritis
      • Products under Development by Companies
        • Table Products under Development by Companies, Gastritis
    • Peritonitis
      • Pipeline Overview
        • Table Figure 8: Number of Products under Development for Peritonitis
        • Table Number of Products under Development for Peritonitis
      • Pipeline by Companies
        • Table Figure 9: Number of Products under Development by Companies, Peritonitis
        • Table Number of Products under Development by Companies, Peritonitis
      • Products under Development by Companies
        • Table Products under Development by Companies, Peritonitis
  • Therapeutics Assessment
    • Gastroenteritis
      • Assessment by Target
        • Table Figure 10: Number of Products by Targets, Gastroenteritis
        • Table Figure 11: Number of Products by Stage and Targets, Gastroenteritis
        • Table Number of Products by Stage and Target, Gastroenteritis
      • Assessment by Mechanism of Action
        • Table Figure 12: Number of Products by Mechanism of Actions, Gastroenteritis
        • Table Figure 13: Number of Products by Stage and Mechanism of Actions, Gastroenteritis
        • Table Number of Products by Stage and Mechanism of Action, Gastroenteritis
      • Assessment by Route of Administration
        • Table Figure 14: Number of Products by Routes of Administration, Gastroenteritis
        • Table Figure 15: Number of Products by Stage and Routes of Administration, Gastroenteritis
        • Table Number of Products by Stage and Route of Administration, Gastroenteritis
      • Assessment by Molecule Type
        • Table Figure 16: Number of Products by Molecule Types, Gastroenteritis
        • Table Figure 17: Number of Products by Stage and Molecule Types, Gastroenteritis
        • Table Number of Products by Stage and Molecule Type, Gastroenteritis
    • Enterocolitis
      • Assessment by Target
        • Table Figure 18: Number of Products by Targets, Enterocolitis
        • Table Figure 19: Number of Products by Stage and Targets, Enterocolitis
        • Table Number of Products by Stage and Target, Enterocolitis
      • Assessment by Mechanism of Action
        • Table Figure 20: Number of Products by Mechanism of Actions, Enterocolitis
        • Table Figure 21: Number of Products by Stage and Mechanism of Actions, Enterocolitis
        • Table Number of Products by Stage and Mechanism of Action, Enterocolitis
      • Assessment by Route of Administration
        • Table Figure 22: Number of Products by Stage and Routes of Administration, Enterocolitis
        • Table Number of Products by Stage and Route of Administration, Enterocolitis
      • Assessment by Molecule Type
        • Table Figure 23: Number of Products by Molecule Types, Enterocolitis
        • Table Figure 24: Number of Products by Stage and Molecule Types, Enterocolitis
        • Table Number of Products by Stage and Molecule Type, Enterocolitis
    • Gastritis
      • Assessment by Target
        • Table Figure 25: Number of Products by Targets, Gastritis
        • Table Figure 26: Number of Products by Stage and Targets, Gastritis
        • Table Number of Products by Stage and Target, Gastritis
      • Assessment by Mechanism of Action
        • Table Figure 27: Number of Products by Mechanism of Actions, Gastritis
        • Table Figure 28: Number of Products by Stage and Mechanism of Actions, Gastritis
        • Table Number of Products by Stage and Mechanism of Action, Gastritis
      • Assessment by Route of Administration
        • Table Figure 29: Number of Products by Routes of Administration, Gastritis
        • Table Figure 30: Number of Products by Stage and Routes of Administration, Gastritis
        • Table Number of Products by Stage and Route of Administration, Gastritis
      • Assessment by Molecule Type
        • Table Figure 31: Number of Products by Molecule Types, Gastritis
        • Table Figure 32: Number of Products by Stage and Molecule Types, Gastritis
        • Table Number of Products by Stage and Molecule Type, Gastritis
    • Peritonitis
      • Assessment by Target
        • Table Figure 33: Number of Products by Targets, Peritonitis
        • Table Figure 34: Number of Products by Stage and Targets, Peritonitis
        • Table Number of Products by Stage and Target, Peritonitis
      • Assessment by Mechanism of Action
        • Table Figure 35: Number of Products by Mechanism of Actions, Peritonitis
        • Table Figure 36: Number of Products by Stage and Mechanism of Actions, Peritonitis
        • Table Number of Products by Stage and Mechanism of Action, Peritonitis
      • Assessment by Route of Administration
        • Table Figure 37: Number of Products by Routes of Administration, Peritonitis
        • Table Figure 38: Number of Products by Stage and Routes of Administration, Peritonitis
        • Table Number of Products by Stage and Route of Administration, Peritonitis
      • Assessment by Molecule Type
        • Table Figure 39: Number of Products by Molecule Types, Peritonitis
        • Table Figure 40: Number of Products by Stage and Molecule Types, Peritonitis
        • Table Number of Products by Stage and Molecule Type, Peritonitis
  • Companies Involved in Therapeutics Development
    • Gastroenteritis
      • Kyowa Hakko Kirin Co Ltd
        • Table Gastroenteritis – Pipeline by Kyowa Hakko Kirin Co Ltd
      • Medicago Inc
        • Table Gastroenteritis – Pipeline by Medicago Inc
      • Ology Bioservices Inc
        • Table Gastroenteritis – Pipeline by Ology Bioservices Inc
      • RedHill Biopharma Ltd
        • Table Gastroenteritis – Pipeline by RedHill Biopharma Ltd
      • Regeneron Pharmaceuticals Inc
        • Table Gastroenteritis – Pipeline by Regeneron Pharmaceuticals Inc
      • Takeda Pharmaceutical Co Ltd
        • Table Gastroenteritis – Pipeline by Takeda Pharmaceutical Co Ltd
      • UMN Pharma Inc
        • Table Gastroenteritis – Pipeline by UMN Pharma Inc
      • Vaxart Inc
        • Table Gastroenteritis – Pipeline by Vaxart Inc
    • Enterocolitis
      • Avexegen Therapeutics Inc
        • Table Enterocolitis – Pipeline by Avexegen Therapeutics Inc
      • Infant Bacterial Therapeutics AB
        • Table Enterocolitis – Pipeline by Infant Bacterial Therapeutics AB
      • Leadiant Biosciences Inc
        • Table Enterocolitis – Pipeline by Leadiant Biosciences Inc
      • ProMetic Life Sciences Inc
        • Table Enterocolitis – Pipeline by ProMetic Life Sciences Inc
    • Gastritis
      • BCWorld Pharm Co Ltd
        • Table Gastritis – Pipeline by BCWorld Pharm Co Ltd
      • Daewon Pharm Co Ltd
        • Table Gastritis – Pipeline by Daewon Pharm Co Ltd
      • Daewoong Pharmaceutical Co Ltd
        • Table Gastritis – Pipeline by Daewoong Pharmaceutical Co Ltd
      • Kyowa Hakko Kirin Co Ltd
        • Table Gastritis – Pipeline by Kyowa Hakko Kirin Co Ltd
      • Recce Ltd
        • Table Gastritis – Pipeline by Recce Ltd
      • RedHill Biopharma Ltd
        • Table Gastritis – Pipeline by RedHill Biopharma Ltd
      • Sequella Inc
        • Table Gastritis – Pipeline by Sequella Inc
    • Peritonitis
      • GlaxoSmithKline Plc
        • Table Peritonitis – Pipeline by GlaxoSmithKline Plc
      • Nosopharm SAS
        • Table Peritonitis – Pipeline by Nosopharm SAS
      • Oncodesign SA
        • Table Peritonitis – Pipeline by Oncodesign SA
      • SynAct Pharma AB
        • Table Peritonitis – Pipeline by SynAct Pharma AB
  • Dormant Projects
    • Gastroenteritis
      • Table Gastroenteritis – Dormant Projects
    • Enterocolitis
      • Table Enterocolitis – Dormant Projects
    • Gastritis
      • Table Gastritis – Dormant Projects
    • Peritonitis
      • Table Peritonitis – Dormant Projects
  • Discontinued Products
    • Gastroenteritis
      • Table Gastroenteritis – Discontinued Products
  • Product Development Milestones
    • Gastroenteritis
      • Featured News & Press Releases
    • Enterocolitis
      • Featured News & Press Releases
    • Gastritis
      • Featured News & Press Releases
    • Peritonitis
      • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report